The Zhitong Finance App learned that the Hong Kong stock prospectus submitted by Chengdu Yiling Biomedical Technology Co., Ltd. (abbreviation: Qiling Biotech) on January 13, 2026 expired for 6 months and expired on July 13, 2026. Jefferies and CICC are its co-sponsors.

According to the previous prospectus, Qianling Biotech is a late clinical biotechnology company dedicated to integrating structural biology, artificial intelligence, and clinical-related disease models to develop highly differentiated small-molecule therapeutics with first-of-its-kind or best-in-class potential.

Genesis Biotech is committed to addressing critical unmet medical needs in the fields of hematologic diseases, tumors, central nervous system, and immune/inflammatory diseases. The company has established a strong and diversified pipeline of eight proprietary assets, covering both clinical and pre-clinical stages.

As of January 5, 2026, Qianling Biotech's pipeline includes two core products (namely flunotinib maleate and preestat mesylate for injection), two additional clinical-stage drug candidates (i.e. ZL-82 and ZL-85), and four pre-clinical drug candidates (i.e. ZL-65, ZL-69, ZL-59 and ZL-89). Two drug candidates have entered phase 3 registered clinical trials, including flunotinib maleate (FM) for myelofibrosis and prestatal mesylate (PM) for relapsed/refractory diffuse large B-cell lymphoma.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.